Dirk Waldschmidt

TL;DR: The progressive accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in NASH-affected livers provides a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.

TL;DR: The CONKO-005 study is the first study to investigate the combination of chemotherapy and a targeted therapy in the adjuvant treatment of PDAC and found that adding erlotinib to gemcitabine did not improve DFS or overall survival over Gem.

TL;DR: In this article, Infigratinib is a selective, ATP-competitive inhibitor of fibroblast growth factor receptors (FGFR2) in patients with locally advanced or metastatic cholangiocarcinoma.

TL;DR: Anti-EGFR treatment with the tyrosine kinase inhibitor erlotinib, as well as chemotherapy intensification by application of the FOLFIRINOX regimen, both significantly improved overall survival in randomised phase 3 trials.

TL;DR: The primary endpoint was surgical conversion rate (complete macroscopic tumour resection) in the randomised population by intention-to-treat analysis, which was assessed by surgical exploration in all patients with at least stable disease after completion of induction chemotherapy.